pharma

Targeting profitable foreign firms operating in China at a time of slowing economic growth seems counterproductive and is a reversal from the past.

Indian pharma company spins off contract research arm, hoping markets will regain a solid footing after Monday's sharp fall.

The US private equity firm raises $241.5 million after paring stake in the Nasdaq-listed biopharmaceutical firm.

The mainland Chinese biotech firm generated strong demand, with the retail tranche of the offering on the Hong Kong bourse 200-times oversubscribed.

Parent Biocon hopes the CRO's strong growth profile and expansion plans will mitigate recent downturn in the Indian equity market

The Chinese private equity firm takes advantage of scorching Hong Kong capital markets to divest holding in mainland pharma firm.

Fosun outbid several rivals after agreeing to pay a revised €459.8 million for the 96% stake in Espirito Santo Saude.

US pharmaceutical distributor Cardinal Health agrees to pay $470 million for China’s largest pharmaceutical importer, Zuellig Pharma China, known locally as Yong Yu.

Can Cipla do for bird flu what it has already done for Aids?